Engineered repressors are potent inhibitors of androgen receptor activity

Prostate cancer growth is dependent upon the Androgen Receptor (AR) pathway, hence therapies for this disease often target this signalling axis. Such therapies are successful in the majority of patients but invariably fail after a median of 2 years and tumours progress to a castrate resistant stage...

Descripción completa

Detalles Bibliográficos
Autores principales: Brooke, Greg N., Powell, Sue M., Lavery, Derek N., Waxman, Jonathan, Buluwela, Laki, Ali, Simak, Bevan, Charlotte L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011597/
https://www.ncbi.nlm.nih.gov/pubmed/24659630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011597/
https://www.ncbi.nlm.nih.gov/pubmed/24659630

Ejemplares similares